3 Reasons I've Been Aggressively Buying Intercept Pharmaceuticals
I admit it: I love trying to catch a falling knife. Sometimes you get sliced in the process, while at other times you leave vindicated by having gone against the grain. My belief is that small-cap biotech Intercept Pharmaceuticals (NASDAQ: ICPT) will fall into that latter description when all is said and done.
There's no masking the fact that Intercept has had a miserable year. Shares are down 43% since the year began, and 63% over the trailing two-year period. This roller-coaster ride is plainly the result of Ocaliva, the company's lone approved drug from the Food and Drug Administration (FDA).
Image source: Getty Images.
Source: Fool.com
